Evidence map›Paper›PMID 14581931›Full record

Trial reportMolecular psychiatry2004

Erythropoietin: a candidate compound for neuroprotection in schizophrenia.

H Ehrenreich, D Degner, J Meller, M Brines, M Béhé, M Hasselblatt, H Woldt, P Falkai, F Knerlich, S Jacob and 7 more

Open access · greenAbstract readClinical TrialControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Molecular psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 206 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Erythropoietin enhances hippocampal response during memory retrieval in humans.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007
    Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  13. Erythropoietin and Erythropoietin Receptor Levels and Their Diagnostic Values in Drug-naïve Patients with Generalized Anxiety Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

H EhrenreichMax-Planck-Institute for Experimental Medicine and Department of Psychiatry, Georg-August-University, Goettingen, Germany. ehrenreich@em.mpg.de
D Degner
J Meller
M Brines
M Béhé
M Hasselblatt
H Woldt
P Falkai
F Knerlich
S Jacob
N von Ahsen
W Maier
W Brück
E Rüther
A Cerami
W Becker
A-L Sirén
Max Planck Institute for Dynamics and Self-Organization · DEUniversity of Göttingen · DEUniversity of Bonn · DEWilliam K. Warren Foundation · USMax Planck Institute of Experimental Medicine · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin (EPO) is a candidate compound for neuroprotection in human brain disease capable of combating a spectrum of pathophysiological processes operational during the progression of schizophrenic psychosis. The purpose of the present study was to prepare the ground for its application in a first neuroprotective add-on strategy in schizophrenia, aiming at improvement of cognitive brain function as well as prevention/slowing of degenerative processes. Using rodent studies, primary hippocampal neurons in culture, immunohistochemical analysis of human post-mortem brain tissue and nuclear imaging technology in man, we demonstrate that: (1) peripherally applied recombinant human (rh) EPO penetrates into the brain efficiently both in rat and humans, (2) rhEPO is enriched intracranially in healthy men and more distinctly in schizophrenic patients, (3) EPO receptors are densely expressed in hippocampus and cortex of schizophrenic subjects but distinctly less in controls, (4) rhEPO attenuates the haloperidol-induced neuronal death in vitro, and (4) peripherally administered rhEPO enhances cognitive functioning in mice in the context of an aversion task involving cortical and subcortical pathways presumably affected in schizophrenia. These observations, together with the known safety of rhEPO, render it an interesting compound for neuroprotective add-on strategies in schizophrenia and other human diseases characterized by a progressive decline in cognitive performance.

Indexed as

AdultAgedAged, 80 and overAnimalsAntipsychotic AgentsCell DeathCells, CulturedCognitionErythropoietinFemaleHaloperidolHumansIndium RadioisotopesInjections, IntraperitonealMaleMiceAntipsychotic AgentsErythropoietinHaloperidolIndium RadioisotopesNeuroprotective AgentsRecombinant Proteins

Identifiers

PMID14581931
OpenAlexW2013177525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.